Skip to main content
. 2023 Jul 10;37(7):655–660. doi: 10.1007/s40263-023-01023-6

Fig. 2.

Fig. 2

Adult Investigator Symptom Rating Scale (AISRS) at baseline, on atomoxetine (Atom), on extended-release viloxazine (VER). *p < 0.005. **p < 0.001. ADHD attention-deficit hyperactivity disorder, AISRS Adult Investigator Symptom Rating Scale, Atom atomoxetine, HI hyperactivity/impulsivity, IA inattentive, VER viloxazine extended-release